

Contents

Part 1. Peritoneal Carcinomatosis: Basic Concepts

1. Structure and Function of Mesothelial Cells	1
Introduction.....	1
Structure of Mesothelial Cells	1
Mesothelial Cell Functions.....	3
Slippery Protective Layer.....	3
Inflammation and Immune Response	4
Tissue Repair.....	6
Fibrin Regulation	6
Role of Mesothelial Cells in Tumour Dissemination	7
Cell Adhesion.....	7
Cell Invasion	10
Tumour Growth.....	11
Summary and Conclusions	12
References.....	12
2. Molecular Biology of Peritoneal Carcinomatosis.....	21
Introduction.....	21
Peritoneal Tumour Dissemination	22
Mesothelial Adhesion	22
Mesothelial Invasion.....	24
Stromal Invasion and Proliferation.....	27
Tumour-Peritoneal Angiogenesis	30
Summary	30
References.....	31
3. Role of Adhesion Molecules in Locoregional Cancer Spread	35
The Micro-ecosystem of Peritoneal Carcinomatosis.....	35
Homotypic Cell-Cell Adhesion by the Cadherins	37
Heterotypic Cell-Cell and Cell-Matrix Adhesion by the Integrins	40
Other Adhesion Compounds relevant for Peritoneal Carcinomatosis.....	42
CD44 and Hyaluronate.....	42
Sialyl Lewis and E-selectin.....	43
CA 125 and Mesothelin	43
L1 and Neuropilin-1	44
Other Adhesion Molecules in the Peritoneum	44
Conclusion and Future Perspectives	44
Acknowledgements.....	45
References	45

4. Surgical Trauma, Minimal Residual Disease and Locoregional Cancer	
Recurrence	51
Introduction	51
Minimal Residual Disease following Surgery.....	51
Tumour Associated Factors	52
Surgery Related Factors.....	52
Tumour Seeding during Laparoscopy.....	53
Postoperative Factors	54
The Link between Residual Tumour Growth and Surgery	55
The importance of Inflammation	55
Surgery and Tumour Dormancy	57
Prevention and Treatment of Residual Tumour Growth	58
Prevention of Surgical Trauma	58
Nonspecific Intraperitoneal Therapy	58
Intraperitoneal Chemotherapy	58
Inhibition of the Angiogenic Switch and Reversal of Tumour Dormancy..	59
Inhibition of the Inflammatory Response	59
Inhibition of Adhesion of Free Intraperitoneal Cancer Cells	60
Summary and Conclusion.....	60
References	61
 5. Pseudomyxoma Peritonei Syndrome: Classification of Appendiceal	
Mucinous Tumours	71
Introduction	71
‘Mucocele’	71
Mucosal Hyperplasia and Hyperplastic Polyp	72
Serrated Adenoma (Mixed Hyperplastic-Adenomatous Polyp).....	74
Mucinous Adenoma (Mucinous Cystadenoma)	75
Mucinous Neoplasm of Uncertain Malignant Potential (M-UMP).....	79
Mucinous Neoplasm of Low Malignant Potential (M-LMP).....	81
Adenocarcinoma (Mucinous, Intestinal, and Signet Ring Types)	86
Goblet Cell and Tubular Carcinoids.....	89
‘Pseudomyxoma Peritonei Syndrome’	92
Conclusion	102
References	103
 6. The Pathogenesis of Malignant Ascites.....	109
Introduction	109
Anatomical and Physiological Considerations.....	109
Anatomy of the Peritoneal Membrane.....	109
The Peritoneal Lymphatic System	110
Characteristics of Malignant Ascites - Intraperitoneal Protein	
Accumulation.....	111
Impaired Drainage or Increased Production?	111

Starling's law of Capillary Hemodynamics	112
Increased Capillary Permeability	113
Increased Filtration Surface Area	114
Increased Hydraulic Pressure Difference.....	114
Decreased Oncotic Pressure Difference.....	115
Conclusion	115
References.....	115
7. Natural History of Peritoneal Carcinomatosis from Digestive Origin.....	119
Introduction.....	119
Aetiology of Peritoneal Carcinomatosis.....	119
Clinical Features of Peritoneal Carcinomatosis from Digestive Origin.....	120
Gastric Cancer.....	121
Colorectal Cancer.....	123
Pancreatic Cancer.....	123
Cancer with Unknown Primary.....	123
Natural History of Peritoneal Carcinomatosis.....	123
Discussion.....	127
References.....	128
 Part 2. The Rationale for Intraperitoneal Heat and Drug Therapy	
 8. Intraperitoneal Drug Therapy: Physical and Biological Principles.....	131
Background.....	131
IP Versus Systemic (IV) Chemotherapy	132
Pharmacokinetic Advantage.....	132
Compartmental Approach to IP Pharmacokinetics.....	133
Distributed Model and Challenges of the Peritoneal Barrier in Neoplasms ..	135
Anatomic Peritoneum.....	136
Interstitial and Tumour Microenvironment	137
Microcirculation.....	139
Summary of Neoplastic versus Normal Peritoneal Barrier.....	140
Importance of Contact Area to Intraperitoneal Chemotherapy	141
Penetration of Antineoplastic Agents	142
Intraperitoneal Chemotherapy with Small Molecular Weight Drugs	143
Intraperitoneal Therapy with Macromolecular Agents.....	144
Acknowledgment.....	145
References.....	145
 9. Current Status of Intraperitoneal Antineoplastic Drug Delivery	153
Intraperitoneal Chemotherapy: Historical Perspective.....	153
The “Dedrick Model” and Pre-clinical Evaluation of Intraperitoneal	
Chemotherapy.....	153
Penetration of Cytotoxic Antineoplastic Agents into Tumour Tissue	154

Drug Delivery by Direct Penetration versus Capillary Flow.....	155
Phase I Trial Experience with Intraperitoneal Antineoplastic Drug Delivery	156
Phase II Trials of Intraperitoneal Antineoplastic Drug Delivery	157
Phase III Trials of Cisplatin-based Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer.....	159
Options for Use of Primary IP Chemotherapy of Ovarian Cancer	161
Other Potential Uses of Intraperitoneal Antineoplastic Drug Delivery in the Management of Ovarian Cancer.....	162
Randomized Trial Experience with Intraperitoneal Antineoplastic Drug Delivery in Non-ovarian Cancers.....	162
References	163
10. The Biologic Rationale of Hyperthermia	171
Abstract.....	171
Introduction	171
Basic Principles of Hyperthermic Cell Death	174
Molecular and Cellular Effectors of Hyperthermia.....	176
Alterations of the Tumour Microenvironment	177
Hyperthermia and the Immune System	178
Cellular Immune Response.....	178
Heat Shock Proteins	179
Summary.....	180
References	180
11. Interactions between Hyperthermia and Cytotoxic Drugs	185
Abstract.....	185
Introduction	185
Principles of heat-drug interaction	187
Hyperthermia and drug resistance	188
Pharmacological studies	189
Heat interactions of novel compounds	189
Summary.....	190
References	191
12. Pharmacodynamic Aspects of Intraperitoneal Cytotoxic Therapy.....	195
Introduction	195
General Pharmacodynamic Aspects of Intraoperative Intraperitoneal Chemotherapy.....	195
Pharmacodynamics of Cytotoxic Drugs used with HIPEC.....	197
Alkylating Drugs.....	198
Platinum Compounds.....	199
Topoisomerase Interactive Agents.....	202
Antimetabolites	203
Antimicrotubule Agents.....	204
Approaches to Increase Tumour Drug Distribution	205
Increasing Drug Supply	205

Enhancing Drug Penetration	206
Summary and Conclusion.....	207
References.....	207

Part 3. Cytoreductive Surgery for Peritoneal Carcinomatosis: Techniques and Methods

13. Patient Selection for Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion.....	215
Introduction.....	215
Indications for Cytoreduction and HIPEC.....	216
Pseudomyxoma Peritonei.....	216
Colorectal Cancer.....	218
Gastric Cancer.....	218
Ovarian Cancer.....	219
Peritoneal Mesothelioma.....	219
Peritoneal Sarcomatosis.....	220
Patient Selection	220
Preoperative Imaging.....	222
Repeat Operations.....	224
References.....	225
14. Staging and Scoring of Peritoneal Carcinomatosis.....	231
Introduction.....	231
Extent of Prior Surgery.....	232
Prior Surgery Score (PSS).....	232
Extent and Distribution of Disease.....	233
Carcinomatosis Staging by the Japanese Research Society for Gastric Cancer (P-Score)	234
Japanese Research Society for Gastric Cancer P-Score	234
Gilly Staging for Peritoneal Carcinomatosis	234
Peritoneal Cancer Index (PCI).....	235
Simplified Peritoneal Cancer Index	238
Involved Regions (N-score)	238
Assessment of Completeness or Extent of Surgery.....	239
Completeness of Cytoreduction Score.....	240
Residual Disease (R) - Score	240
Extent of Surgery.....	241
Extent of Surgery Score	242
Level of Cytoreduction	242
Conclusion	242
References.....	243

15. Peritonectomy Procedures.....	247
Introduction	247
Electroevaporative surgery	247
Patient Positioning	248
Construction of the Surgical Field to provide Simultaneous Exposure of the Abdomen and Pelvis	249
Parietal Peritoneal Stripping from the Anterior Abdominal Wall	250
Stripping the Visceral Peritoneum from the Surface of the Bladder	250
Parietal Peritoneal Dissection to the Paracolic Sulcus and Beyond	251
Peritoneal Stripping from Beneath the Left Hemidiaphragm	252
Greater Omentectomy and Splenectomy with Completion of the Left Subphrenic Peritonectomy	253
Peritoneal Stripping from Beneath the Right Hemidiaphragm.....	254
Removal of an Envelope of Tumour from Beneath the Right Hemidiaphragm, from the Right Subhepatic Space, and from the Surface of the Liver	255
Completed Right Subphrenic Peritonectomy	256
Cholecystectomy with Resection of the Hepatoduodenal Ligament	256
Circumferential Resection of the Hepatogastric Ligament and Lesser Omentum by Digital Dissection.....	257
Limits of the Lesser Omentectomy with Stripping of the Floor of the Omental Bursa.....	258
Limits of the Complete Pelvic Peritonectomy	260
Resection of Rectosigmoid Colon, Uterus, and Cul-de-sac of Douglas....	260
Preparation for Perioperative Intraperitoneal Chemotherapy	262
Discussion.....	263
References	264
16. Continuous Peritoneal Perfusion: Techniques, Methods and Applications	265
Introduction	265
Methods of Hyperthermic Intraperitoneal Chemotherapy	265
Open Perfusion Methods	266
Partially Closed and Closed Perfusion Methods	267
Safety Considerations for HIPEC.....	269
Technical Parameters of Hyperthermic Chemoperfusion	270
Cytostatic Agents Suitable for HIPEC.....	270
Intraperitoneal Temperature.....	270
Carrier solution	271
Volume.....	271
Duration	271
Flow rate	272
Conclusions	272
References	272
17. Handling of Chemotherapeutic Drugs in the OR: Hazards and Safety Considerations	275
Introduction	275

Exposure and Effect Studies	276
Routes and mechanisms of exposure.....	277
Inhalation of Airborne Compounds	277
Ingestion and Eye Contact	278
Skin Contact	279
Injection through Accidental Injury with Sharp Tools	279
Recommendations for Safety Precautions	279
Organizational measures.....	280
Use of Technical and Personal Protective Equipment.....	281
Spill Management, Cleaning and Decontamination Protocols	282
Proper Waste Handling and Disposal	283
Information and Training	284
Medical Surveillance and Monitoring.....	285
References.....	286

Part 4. Clinical Results of Surgery with or without Intraperitoneal Heated Drug Therapy

18. Results of Cytoreduction followed by HIPEC in Carcinomatosis of

Colorectal Origin	291
Introduction.....	291
Surgery for Peritoneal Carcinomatosis of Colorectal Origin	292
Prognostic Factors	294
Completeness of Cytoreduction	294
Extent of Disease before Surgery.....	295
Other Prognostic Factors.....	295
Complications of Surgery.....	296
The Learning Curve of Cytoreduction with HIPEC.....	297
Conclusion	299
References.....	299

19. HIPEC with Oxaliplatin in the Treatment of Peritoneal Carcinomatosis of Colorectal Origin

Introduction.....	303
Patient Eligibility and Surgical Procedures.....	304
Hyperthermic Intraperitoneal Chemotherapy (HIPEC).....	304
Results of a Phase I Study of HIPEC with Oxaliplatin	305
Methods.....	305
Results	305
Conclusion.....	306
Results of a Phase I Study with Oxaliplatin using Hypotonic Solutions	306
Introduction	306
Methods.....	306
Results	307

Results of a Phase II Study of HIPEC with Oxaliplatin.....	307
Patients and methods.....	307
Results	308
Discussion	309
Conclusion	310
Comparison of HIPEC with Oxaliplatin versus Standard Systemic Chemotherapy.....	310
HIPEC group.....	310
Standard Group	310
Overall survival rates	311
Discussion	312
Phase I study of HIPEC combining Oxaliplatin and Irinotecan.....	313
Methods.....	313
Results	313
Conclusion	313
Relation between the Extent of Cytoreductive surgery and the Rate of Postoperative Hematological Toxicity	314
Background	314
Methods.....	314
Results	314
Conclusion	315
Future Directions and Conclusion	315
Aknowledgement.....	316
References	316
 20. Clinical Results of Cytoreduction and HIPEC in Pseudomyxoma Peritonei	 319
Introduction	319
Site of Origin of PMP	319
Pathological Classification of Appendiceal Neoplasms.....	320
Clinical Trials of Cytoreduction and Intraperitoneal Chemotherapy	321
Conclusion	324
References	325
 21. The Impact of Therapy in the Treatment of Pseudomyxoma Peritonei. 329	
Introduction	329
Memorial Sloan-Kettering Cancer Center Experience.....	331
Methods	332
Clinicopathologic Features	333
Operative Results.....	333
Long term overall survival	335
Evaluating the Impact of Therapy for PMP	336
References	340

22. Clinical Results of Cytoreduction and HIPEC for Malignant Peritoneal Mesothelioma	343
Introduction.....	343
Results of Cytoreduction and HIPEC	345
Summary	352
References.....	353
 23. Cytoreduction and Intraperitoneal Chemotherapy for Carcinomatosis from Gastric Cancer	357
Introduction.....	357
Diagnosis of Peritoneal Carcinomatosis.....	357
Results of Systemic Chemotherapy in the Treatment of PC of Gastric Origin.....	360
Treatment of PC of Gastric Origin with Intraperitoneal Chemotherapy	362
Perioperative Intraperitoneal Chemotherapy	363
Neoadjuvant Intraperitoneal and Systemic Chemotherapy.....	363
Hyperthermic Intraperitoneal Chemoperfusion	365
Early Postoperative Intraperitoneal Chemotherapy	368
Peritonectomy Procedures.....	368
Conclusion	369
References.....	369
 24. Cytoreduction and Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Cancer	375
Introduction.....	375
Cytoreductive Surgery	376
Hyperthermic Intraperitoneal Chemotherapy	378
Intraperitoneal Chemotherapy.....	378
Intraperitoneal Hyperthermic Chemotherapy	378
Effects of HIPEC.....	378
Refractory Ovarian Cancer.....	381
Prognostic Factors Affecting Patient Survival	381
Conclusion	382
References.....	382
 25. The role of Neoadjuvant Chemotherapy versus Primary Surgery in the Management of Stage III Ovarian Cancer	387
Introduction.....	387
Primary Cytoreductive Surgery	388
Biological basis of Cytoreductive Surgery	388
Optimal versus Suboptimal Cytoreductive Surgery	388
Variables influencing Cytoreductive Surgery.....	389
Outcome of Cytoreductive Surgery	390
FIGO Stage IV Disease.....	391
Neoadjuvant Chemotherapy and Interval Cytoreduction.....	392
Neoadjuvant Chemotherapy followed by Interval Cytoreduction after Suboptimal Primary Cytoreduction	392

Neoadjuvant Chemotherapy followed by Interval Cytoreduction as an Alternative to Primary Cytoreduction.....	393
Laparoscopy to select Patients for Neoadjuvant Chemotherapy.....	396
References	397
26. Morbidity and Quality of Life following Cytoreduction and HIPEC.....	403
Introduction	403
Morbidity and Mortality following Cytoreduction and HIPEC	403
Milano National Cancer Institute Experience	406
Bowel Complications following Cytoreduction and HIPEC	410
Quality of Life following Cytoreduction and HIPEC	415
References	415
27. Detection and Treatment of Recurrent Disease after Cytoreduction and HIPEC	419
Follow-up after Cytoreduction	419
Treatment of Recurrent Disease	422
References	423
 Part 5. Nonoperative and Multimodal Management of Peritoneal Carcinomatosis	
28. Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis from Colorectal Cancer	425
Introduction	425
Peritoneal Carcinomatosis in Trials of Systemic Chemotherapy.....	425
Systemic Therapy with 5-Fluorouracil	427
New cytotoxic drugs: Irinotecan and Oxaliplatin.....	430
Oral Fluoropyrimidines.....	432
Antibodies in Treatment of Colorectal Cancer	433
Treatment strategy	435
References	435
29. Systemic Chemotherapy in patients with Peritoneal Carcinomatosis from Non Colorectal Origin	441
Introduction	441
Systemic Therapy	442
Conclusion	445
References	446
30. The Role of Radiotherapy in the treatment of Peritoneal Carcinomatosis	449
Introduction	449
PC Originating from Gastrointestinal Cancers.....	450
PC Originating from Gynaecological Cancers.....	451

PC Originating from Other Cancers	452
Conclusions and Future Prospects for Radiotherapy - the Role of Intensity Modulated Arc Therapy.....	453
References.....	455
31. Medical and Palliative Management of Malignant Ascites	459
Introduction.....	459
Pathophysiology and Diagnosis.....	459
Symptomatic Management by Paracentesis	460
Symptomatic Management by Diuretics	461
Symptomatic Management by Peritoneovenous Shunts	461
New Treatments.....	462
Management of Symptomatic Malignant Ascites	463
References.....	464
 Part 6. Experimental Approaches	
32. Targeted Intraabdominal Chemotherapy for Peritoneal Carcinomatosis	469
Summary	469
Intentions and Basic Concepts of Targeted Chemotherapy	470
Clinical Experience.....	470
Experimental Evidence.....	472
Animals and Experimental Design	472
Cell Culture and Tumour Cell Inoculation	473
Intraperitoneal Treatment.....	473
Assessment of Peritoneal Tumour spread, Tumour Growth and Response to Treatment	474
Tumour Growth and Response to Treatment.....	474
Discussion.....	478
Perspectives	478
References.....	479
33. Immunotherapy of Peritoneal Carcinomatosis	483
Immunological Defence Mechanisms of the Peritoneal Cavity	483
Unspecific Immunotherapy/Cytokines	484
Stimulation of Immunocompetent Cells by Defined Cytokines	484
Antibody Constructs	485
Summary.....	488
References.....	489
34. Intraperitoneal Photodynamic Therapy	493
Introduction.....	493
Mechanisms of PDT Mediated Cell Death.....	494
Preclinical Studies of Intraperitoneal PDT	496

Clinical Applications of Intraperitoneal PDT	499
New Frontiers in Intraperitoneal PDT: Molecularly Targeted Therapy	503
Summary and Conclusions	504
References	505
35. Intraperitoneal Gene Therapy	515
Introduction	515
Vectors.....	515
Gene Therapy Strategies.....	516
Targeting p53 tumour suppressor gene.....	516
Targeting HER-2/neu proto-oncogene.....	517
Other adenovirus based approaches.....	518
Experimental Approaches	519
Conclusion	520
References	520
36. Index	525

<http://www.springer.com/978-0-387-48991-9>

Peritoneal Carcinomatosis: A Multidisciplinary Approach

ceelen, w. (Ed.)

2007, XXXI, 535 p., Hardcover

ISBN: 978-0-387-48991-9